Orchid Pharma Ltd

Orchid Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Orchid Pharma Ltd

₹ 1,084 -0.74%
26 Apr - close price
orchidpharma.com BSE: 524372 NSE : ORCHPHARMA
About

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]

Key Points

Product Portfolio
The Co has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products. Its Product portfolio constitute of API - Cephalosporins - Orals, Cephalosporins - Injectables, Veterinary Products & Non-Antibiotics. [1][2]

Website BSE NSE
  • Market Cap ₹ 5,500 Cr.
  • Current Price ₹ 1,084
  • High / Low ₹ 1,360 / 381
  • Stock P/E 64.4
  • Book Value ₹ 218
  • Dividend Yield 0.00 %
  • ROCE 4.97 %
  • ROE 0.95 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Stock is trading at 4.96 times its book value
  • The company has delivered a poor sales growth of -0.51% over past five years.
  • Company has a low return on equity of -5.65% over last 3 years.
  • Earnings include an other income of Rs.52.0 Cr.
  • Promoter holding has decreased over last 3 years: -28.2%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
103 120 92 128 161 178 131 165 160 210 183 199 221
108 123 95 116 147 152 119 147 146 170 161 175 185
Operating Profit -5 -4 -3 11 14 26 12 18 14 40 22 23 35
OPM % -5% -3% -3% 9% 9% 14% 10% 11% 9% 19% 12% 12% 16%
2 11 3 68 -1 -0 3 6 9 34 2 8 8
Interest 13 12 11 10 7 4 8 9 8 7 6 4 4
Depreciation 29 20 20 20 20 27 22 18 8 7 8 8 9
Profit before tax -45 -25 -31 49 -14 -5 -14 -3 7 59 11 20 30
Tax % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-45 -25 -31 49 -14 -7 -15 -5 8 59 9 20 29
EPS in Rs -10.96 -6.06 -7.57 12.10 -3.40 -1.61 -3.68 -1.32 1.86 14.49 1.85 3.90 5.80
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
1,782 1,874 1,948 1,747 873 797 683 600 484 450 560 666 812
1,437 1,517 1,837 1,429 703 794 659 612 515 421 505 581 692
Operating Profit 345 357 110 317 171 3 24 -12 -31 29 55 84 120
OPM % 19% 19% 6% 18% 20% 0% 4% -2% -6% 7% 10% 13% 15%
77 52 92 156 -28 -59 20 218 24 15 67 52 52
Interest 117 180 523 537 294 347 310 7 6 52 33 33 20
Depreciation 134 154 252 325 145 141 133 130 118 109 87 55 32
Profit before tax 172 75 -573 -389 -296 -544 -399 69 -131 -117 2 48 120
Tax % 9% -29% 2% 49% 6% 9% 12% 0% 0% 0% 0% 0%
156 97 -560 -197 -279 -495 -353 69 -131 -117 -2 46 118
EPS in Rs 22.17 13.84 -79.21 -23.06 -31.37 -55.69 -39.65 7.80 -32.11 -28.55 -0.48 11.35 26.04
Dividend Payout % 14% 22% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: -1%
3 Years: 11%
TTM: 28%
Compounded Profit Growth
10 Years: %
5 Years: 15%
3 Years: 27%
TTM: 588%
Stock Price CAGR
10 Years: 35%
5 Years: 191%
3 Years: -13%
1 Year: 177%
Return on Equity
10 Years: %
5 Years: %
3 Years: -6%
Last Year: 1%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 70 70 70 85 89 89 89 89 41 41 41 41 51
Reserves 999 1,062 310 244 -40 -556 -881 -793 725 612 607 648 1,057
2,079 2,005 3,204 3,211 3,215 3,106 3,202 3,230 566 453 268 331 147
762 801 1,067 521 598 616 715 551 128 132 195 205 237
Total Liabilities 3,910 3,938 4,651 4,061 3,862 3,256 3,125 3,077 1,460 1,237 1,111 1,225 1,492
1,742 2,074 2,584 1,795 1,637 1,497 1,386 1,256 858 670 584 573 564
CWIP 332 352 360 282 280 288 272 278 26 7 10 46 63
Investments 1 1 1 1 1 1 1 0 0 15 45 44 47
1,835 1,511 1,706 1,984 1,944 1,470 1,467 1,542 576 544 472 561 818
Total Assets 3,910 3,938 4,651 4,061 3,862 3,256 3,125 3,077 1,460 1,237 1,111 1,225 1,492

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
332 737 168 -369 212 401 9 12 81 24 92 18
-367 -293 -986 1,334 -1 -176 -28 45 167 67 113 -31
-78 -480 664 -597 -286 -465 33 -0 -250 -165 -217 31
Net Cash Flow -113 -36 -153 367 -76 -240 15 57 -2 -74 -11 18

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 105 22 34 54 130 75 64 73 51 110 111 118
Inventory Days 259 279 187 118 220 196 202 214 254 244 201 217
Days Payable 141 186 220 146 341 402 374 381 182 176 195 173
Cash Conversion Cycle 224 114 -0 26 9 -130 -108 -94 123 179 117 163
Working Capital Days -36 34 -113 86 97 -226 -505 -735 166 305 136 154
ROCE % 10% 8% -3% 1% 1% -4% -4% -5% -6% -5% -2% 5%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
90.00% 90.00% 90.00% 90.00% 89.96% 89.96% 89.96% 89.96% 72.40% 72.40% 69.84% 69.84%
1.82% 1.79% 1.78% 1.61% 1.48% 1.37% 0.86% 0.81% 8.58% 8.08% 4.14% 1.96%
3.67% 3.35% 3.35% 2.97% 2.97% 2.98% 3.94% 2.62% 13.48% 12.46% 14.51% 17.73%
0.00% 0.04% 0.04% 0.04% 0.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
4.51% 4.83% 4.84% 5.39% 5.55% 5.69% 5.22% 6.60% 5.54% 7.05% 11.52% 10.47%
No. of Shareholders 33,37934,79833,53333,69833,67932,71730,89429,52329,13229,19736,93136,720

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls